Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Hanania, A. Boota, C. Fogarty, E. Kerwin, L. Tomlinson, K. Denis-Mize (Houston, TX, Napa, CA, Greenville, SC, Medford, OR, Spartanburg, SC, United States Of America). Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium. Eur Respir J 2008; 32: Suppl. 52, 3621

Member's Comments

No comment yet.

Related content which might interest you: Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 The combination therapy with inhaled tiotropium bromide and transdermal tulobuterol in COPD improves the peripheral airway function Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Combination therapy with maintenance budesonide and formoterol in COPD Source: Eur Respir J 2004; 24: 1070 Year: 2004 Improved lung function and symptom control with formoterol on demand in asthma Source: Eur Respir J 2006; 27: 504-510 Year: 2006 Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006 Comparative effects of formoterol monotherapy versus formoterol plus tiotropium on dynamic hyperinflation and exercise tolerance in COPD Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009 Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009 Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use Source: Eur Respir J 2004; 24: Suppl. 48, 289s Year: 2004 Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018 Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004 Long-term safety of inhaled formoterol in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 14s Year: 2005 Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002 Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004 COPD: Comparison of bronchodilator responsiveness with glycopyrronium and salbutamol Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017